MedTrace Logo

SLS-005 (Trehalose Injection) in the Treatment of Alzheimer's Disease

NCT05332678 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-04-11

No results posted yet for this study

Summary

An open-label, proof-of-concept study to evaluate the safety and treatment effects of SLS-005 in Participants with Alzheimer's Disease (AD) treated once or twice weekly for 52 weeks.

Conditions

Interventions

DRUG

SLS-005 - Once Weekly

Please see Arm description.

DRUG

SLS-005 - Twice Weekly

Please see Arm description.

Sponsors & Collaborators

  • Seelos Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-03
Primary Completion
2023-04-10
Completion
2023-04-10

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05332678 on ClinicalTrials.gov